Push-pull sorbent-based pheresis treatment in an experimental canine endotoxemia model: Preliminary report

International Journal of Artificial Organs

Volumn 22, Issue 3, 1999, Pages 177-188

  Peter, Augustine T ^a   Ash, S R ^a,b,c   Steczko, J ^b   Turek, J J ^a   Blake, D E ^b   Carr, D J ^b   Knab, W R ^b   Bosley, R H ^b  

^a PURDUE UNIVERSITY   (United States)

^b HemoCleanse Incorporated   (United States)

^c St Elizabeth Hospital   (United States)

Author keywords

Cytokines; Endotoxin; Plasma filter; Plate dialyzer

Indexed keywords

BANDPASS FILTERS; BLOOD; BLOOD PRESSURE; CHARCOAL; ESCHERICHIA COLI; SORBENTS; SORPTION;

CYTOKINES; ENDOTOXIN; INTERLEUKIN1; INTERLEUKIN6 (IL6); MEAN ARTERIAL PRESSURE; PLASMA FILTER; PLATE DIALYZER; PUSH PULL; TREATMENT GROUP; TUMOR NECROSIS FACTORS;

SILICA;

ALBUMIN; CALCIUM; CHARCOAL; HEMOGLOBIN; INTERLEUKIN 1; INTERLEUKIN 6; POTASSIUM; SILICON DIOXIDE; SORBENT; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOASSAY; BLOOD CHEMISTRY; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; DEVICE; DOG; ENDOTOXEMIA; ESCHERICHIA COLI; EXTRACORPOREAL CIRCULATION; HEMATOCRIT; HEMOFILTRATION; MEAN ARTERIAL PRESSURE; NONHUMAN;

EID: 0032901917     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139889902200310     Document Type: Article

References (48)

1. Davies MG, Hagen PO. Systemic inflammatory response syndrome. Br J Surg 1997; 84: 920-35.
2. Calandra T, Glauser MP, Schellekens J, et al. Treatment of Gram-negative septic shock with human IgG antibody to E.coli J5: A prospective, double-blind, randomized trial. J Infec Dis 1998; 158: 312-9.
3. Ziegler EJ, Fisher CJ Jr, Sprung CL, et al. Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo controlled trial. N Engl J Med 1991; 324: 429-36.
4. Zeni F, Freeman B, Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment. Crit Care Med 1997; 25: 1095-100.
5. Piper R, Cook DJ, Bone RC, Sibbald WJ. Introducing critical appraisal to studies of animal models investigating novel therapies in sepsis. Crit Care Med 1996; 24: 2059-70.
6. Kramer P, Wigger W, Rieger J, et al. Arteriovenous haemofiltraion. Klin Wochenschr 1977; 55: 1121-22.
7. Gotloib L, Barzilay E, Shustak A, Lev A. Sequential hemofiltration in non-oliguric high capillary permeability pulmonary edema of severe sepsis: preliminary report. Crit Care Med 1984; 12: 997-1000.
8. Gotloib L, Barzilay, Shistak A, et al. Hemofiltration in septic ARDS. The artificial kidney as an artificial endocrine lung. Resuscitation 1986; 13: 123-32.
9. Barzilay E, Kessler D, Berlot G, et al. Use of extracorporeal supportive techniques as additional treatment for septic-induced multiple organ failure patients. Crit Care Med 1989; 17: 634-7.
10. Staubach KH, Rau HG, Kooistra A, et al. Can hemofiltration increase survival time in acute endotoxemia-a porcine shock model. Prog Clin Biol Res 1989; 388: 821-6.
11. Stein B, Pfenninger E, Grunert A, et al. Influence of continuous haemofiltraion on hemodynamics and central blood volume in experimental endotoxic shock. Int Care Med 1990; 16: 494-9.
12. Nahman NS and Middendorf DF. Continuous arteriovenous hemofiltration. Med Clin North America 1990; 74: 975-85.
13. Groeneveld ABJ. Septic shock and multiple organ failure: treatment with hemofiltration. Int Care Med 1990; 16: 489-90.
14. Gomez A, Wang R, Unrun R. Hemofiltration reverses left ventriculuar dysfunction during sepsis in dogs. Anesthesiology 1990; 73: 671-85.
15. Bellomo R, Tipping P, Boyce N. Tumor necrosis factor clearances during veno-venous hemofiltration in the critically ill. ASAIO Transactions 1991; 37: M322-3.
16. Grootendorst AF, VonBommel E, vanderHoven B, van Leengoed L, van Osta G. High-volume hemofiltration improves hemodynamics of endotoxin-induced shock in the pig. J Crit Care 1992; 7: 67-75.
17. Sato T, Orlowski JP, Zborowski M. Experimental study of extracorporeal perfusion for septic shock. ASAIO J 1993; 39: M790-3.
18. Tonnesen E, Hansen MB, Hohndorf K, et al. Cytokines in plasma and ultrafiltrate during continuous arteriovenous haemofiltraion. Anesth Intern Care 1993; 21: 752-8.
19. Lee P, Wager G, Pryor R, Matson J. Effects of filter pore size on efficacy of continuous arteriovenous hemofiltration (CAVH) therapy in improving morbidity and mortality in an immature swine model of Staphylococcus aureus-induced sepsis. Shock 1994; 1 (Suppl): S31.
20. Lonergan JM, Orlowski JP, Sato T, McHugh MJ, Zborowski M. Extracorporeal endotoxin removal in a canine model of septic shock. ASAIO J 1994; 40: M654-7.
21. Freeman BD, Yatsiv I, Natanson C, et al. Continuous arteriovenous hemofiltration does not improve survival in a canine model of septic shock. J Am Coll Surg 1995; 180: 286-92.
22. Bottoms G, Fessler J, Murphy E, et al. Efficacy of convective removal of plasma mediators of endotoxic shock by continuous veno-venous hemofiltration. Shock 1996; 5:149-54.
23. Odnopozov VA, Laterre PF, Traystman RJ, Tsybulkin EK, Winchruch RA, Breslow MJ. Effect of hemocarboperfusion on organ blood flow and survival in porcine endotoxic shock. Crit Care Med 1996; 24: 2020-6.
24. Ash SR, Blake DE, Carr DJ, Harker KD. Push-pull sorbent based pheresis for treatment of acute hepatic failure: the Biologic-Detoxifier/Plasma Filter System. ASAIO J 1998; 44: 129-39.
25. Steczko J, Ash SR, Carr DJ, Blake DE, Bosley R. Cytokines and endotoxin removal from plasma by push-pull sorbent-based pheresis: the Biologic-DTPF System™. Artif Organs, 1999; 23.
26. Ash SR, Steczko J, Carr DJ, Blake DE. Cytokine and bilirubin removal in acute hepatic failure by push-pull sorbent-based pheresis (the Biologic-DTPF System™). Hepatology 1997; 26: 4 (Suppl): 475A.
27. Steczko J, Ash SR, Levy H, Carr DJ, Blake DE. Cytokine removal from plasma of patients with sepsis by the Biologic-DTPF System™. Hepatology 1997; 26: 4 (Suppl): 604A.
28. Steczko J, Ash SR, Blake DE. Cytokine removal from plasma by push-pull sorbent-based pheresis (the Biologic-DTPF). Abstract. ASAIO J 1997; 43: 82.
29. Ash SR, Steczko J, Carr DJ, Blake DE. Cytokine, endotoxin, and bilirubin removal from plasma by push-pull sorbent based pheresis (the Biologic DTPF System). Abstract. Int J Artif Organs 1997; 21: 499.
30. Hesse DG, Tracey KJ, Fong Y, Manogue KR, Palladino MA Jr, Cerami A, Lowry SF. Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet 1988; 166: 147-53.
31. Michie HR, Manogue KR, Spriggs DR, et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 1988; 318: 1481-6.
32. Dinarello CA. Biology of interleukin 1. FASEB J 1988; 2: 108-15.
33. Natanson C. Studies using a canine model to investigate the cardiovascular abnormality of and potential therapies of septic shock. Clin Res 1990; 38: 206-14.
34. Ash SR, Carr DJ, Blake DE, Harker KD. Push-pull sorbent-suspension pheresis for treatment of acute hepatic failure: the BioLogic-DTPF. Abstract. ASAIO J 1996; 42: 11.
35. Bucher N. A safer way to get hemodynamic data. RN 1992; 56-60.
36. Inada K, Endo S, Takahashi M, et al. Establishment of a new perchloric acid treatment method to allow determination of the total endotoxin content in human plasma by limulus test and clinical application. Microbiol and Immunol 1991; 35: 303-14.
37. Hansen MB, Nielsen SE, Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 1989; 119: 203-10.
38. Karavodin LM, Glasebrook AL, Phelps JL. Decline in growth and antibody production of established hybridomas and transfectomas with addition of interleukin 6. Eur J Immunol 1989; 19: 1351-4.
39. Aarden LA, De Groot ER, Schaap OL, Lansdorp PM. Production of hybridoma growth factor by monocytes. Eur J Immunol 1987; 17: 1411-6.
40. Gill J, Hafs HD. Analysis of repeated measurements of animals. J Anim Sci 1971; 33: 331-6.
41. SAS Userís Guide: Statistics. SAS Institute, Inc., Cary, NC (1982).
42. Fessler JF, Bottoms GD, Coppoc GL, et al. Plasma endotoxin concentrations in experimental and clinical equine subjects. Eq Vet J 1989; 7: 24-8.
43. Shapiro L, Gelfund JA. Cytokines. In: Ayres SM, Grenvik A, Holbrook PR, et al, eds. Textbook of Critical Care. Philadelphia: WB Saunders, 1995; 154-61.
44. Natanson C, Fink MP, Ballantyne HK, et al. Gram-negative bacteremia produces both severe systolic and diastolic cardiac dysfunction in canine model that simulates human septic shock. J Clin Invest 1986; 78: 259-70.
45. Natanson C, Hoffman WD, Koev DP, et al. Plasma exchange does not improve survival in a canine model of septic shock. Transfusion 1993; 33: 243-8.
46. Freeman BD, Yatsiv I, Natanson C, et al. Continuous arteriovenous hemofiltration does not improve survival in a canine model of septic shock. Am Coll Surg 1995; 180: 286-97.
47. Quezado ZMN, Natanson C, et al. A controlled trial of HA-1A in a canine model of gram-negative septic shock. JAMA 1993; 269: 2221-7.
48. Levy H, Ash SR, Knab W, Steczko J, Carr DJ, Blake DE. Systemic inflammatory response syndrome (SIRS) treatment by powdered sorbent pheresis: the BioLogic-DTPF System™. ASAIO J 1998; 44: M659-65.